Navigation FDA's Embrace of AI to Speed Up Drug Approvals Leaves Industry Observers Excited, Uneasy
“There are problems with generative AI, and there need to be guardrails and there needs to be human oversight,” said Jason Conaty, counsel at Hogan Lovells.
“There are problems with generative AI, and there need to be guardrails and there needs to be human oversight,” said Jason Conaty, counsel at Hogan Lovells.
